1). Poupard JA., Husain I., Norris RF. Biology of the bifidobacteria. Bacteriol Rev. 1973. 37:136–65.
Article
2). Rhee YK., Han MJ., Choi EC., Kim DH. Hypocholesterolemic activity of Bifidobacteria isolated from a healthy Korean. Arch Pharm Res. 2002. 25:681–4.
3). Sekine K., Ohta J., Onishi M., Tatsuki T., Shimokawa Y., Toida T, et al. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull. 1995. 18:148–53.
4). Hatcher GE., Lambrecht RS. Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J Dairy Sci. 1993. 76:2485–92.
Article
5). Sekine K., Watanabe-Sekine E., Toida T., Kasashima T., Kataoka T., Hashimoto Y. Adjuvant activity of the cell wall of Bifidobacterium infantis for in vivo immune responses in mice. Immunopharmacol Immunotoxicol. 1994. 16:589–609.
6). Hart AL., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004. 53:1602–9.
Article
7). Park JH., Um JI., Lee BJ., Goh JS., Park SY., Kim WS, et al. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell Immunol. 2002. 219:22–7.
8). Bernet MF., Brassart D., Neeser JR., Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol. 1993. 59:4121–8.
Article
9). Fedorak RN., Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004. 10:286–99.
Article
10). Salminen S., Salminen E. Lactulose lactic acid bacteria, intestinal microecology and mucosal protection. Scand J Gastroenterol Suppl. 1997. 222:45–8.
Article
11). Boulinier G. Arthur Keith and the first settlement of human being in Malta. Two subversive teeth. Hist Sci Med. 2004. 38:37–48.
12). He F., Morita H., Ouwehand AC., Hosoda M., Hiramatsu M., Kurisaki J, et al. Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains. Microbiol Immunol. 2002. 46:781–5.
13). Park SY., Ji GE., Ko YT., Jung HK., Ustunol Z., Pestka JJ. Potentiation of hydrogen peroxide, nitric oxide, and cytokine production in RAW 264.7 macrophage cells exposed to human and commercial isolates of Bifidobacterium. Int J Food Microbiol. 1999. 46:231–41.
14). Young SL., Simon MA., Baird MA., Tannock GW., Bibiloni R., Spencely K, et al. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clin Diagn Lab Immunol. 2004. 11:686–90.
Article
15). Moore KW., de Waal Malefyt R., Coffman RL., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001. 19:683–765.
Article
16). Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004. 22:531–62.
17). Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002. 2:389–400.
18). Niers LE., Timmerman HM., Rijkers GT., van Bleek GM., van Uden NO., Knol EF, et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy. 2005. 35:1481–9.
Article
19). Gill HS., Rutherfurd KJ., Cross ML., Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001. 74:833–9.